Table 3.
Treatment-related toxicity and treatment compliance
| Adverse event | LD | ED | ||||
|---|---|---|---|---|---|---|
| High-CXI group (n = 83) | Low-CXI group (n = 24) | p | High-CXI group (n = 123) | Low-CXI group (n = 37) | p | |
| Hematological toxicity ≥ grade 3 | ||||||
| Anemia | 17 (20.5%) | 7 (29.2%) | 0.369 | 21 (17.1%) | 9 (24.3%) | 0.322 |
| Neutropenia | 78 (94.0%) | 21 (87.5%) | 0.375 | 108 (87.8%) | 29 (78.4%) | 0.152 |
| Febrile neutropenia | 16 (19.3%) | 5 (20.8%) | > 0.998 | 17 (13.8%) | 8 (21.6%) | 0.252 |
| Thrombocytopenia | 21 (25.3%) | 7 (29.2%) | 0.704 | 27 (22.0%) | 10 (27.0%) | 0.521 |
| Median treatment cycles (IQR) | 6 (4–6) | 5.5 (3–6) | 0.118 | 6 (4–6) | 3 (2–6) | < 0.001 |
| Early discontinuation of treatment | 14 (16.9%) | 9 (37.5%) | 0.030 | 14 (11.4%) | 10 (27.0%) | 0.019 |
| Treatment-related mortality | 4 (4.8%) | 3 (12.5%) | 0.186 | 3 (2.4%) | 4 (10.8%) | 0.051 |
LD limited-stage disease, ED extensive-stage disease, CXI cachexia index, IQR interquartile range